Published in Eur J Clin Pharmacol on February 18, 2003
The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol (2006) 2.70
Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma (2007) 1.76
Statins and the vascular endothelial inflammatory response. Trends Immunol (2007) 1.43
Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke. Hum Genet (2012) 1.42
Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res (2008) 1.24
Multifunctional drugs for head injury. Neurotherapeutics (2009) 1.16
Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10
Hypercholesterolemia and microvascular dysfunction: interventional strategies. J Inflamm (Lond) (2010) 1.06
Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 1.05
Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res (2004) 1.05
A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol (2011) 1.02
Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling? Transl Res (2010) 0.99
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Malar J (2011) 0.96
Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol (2006) 0.96
Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment. Curr Opin Pharmacol (2010) 0.91
Long-term benefits after treatment of traumatic brain injury with simvastatin in rats. Neurosurgery (2009) 0.89
Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. Mol Cell Biol (2011) 0.88
Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med (2005) 0.87
Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury. Acta Pharmacol Sin (2012) 0.86
Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res (2007) 0.84
Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev Neurother (2009) 0.84
The Arginine/ADMA Ratio Is Related to the Prevention of Atherosclerotic Plaques in Hypercholesterolemic Rabbits When Giving a Combined Therapy with Atorvastatine and Arginine. Int J Mol Sci (2015) 0.83
Distribution of endogenous farnesyl pyrophosphate and four species of lysophosphatidic acid in rodent brain. Int J Mol Sci (2010) 0.83
Heat shock proteins modulate keloid formation. Eplasty (2011) 0.82
High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br J Pharmacol (2005) 0.82
Cytoadherence and severe malaria. Malays J Med Sci (2012) 0.81
Prevention of arterial stiffening by using low-dose atorvastatin in diabetes is associated with decreased malondialdehyde. PLoS One (2014) 0.81
Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy. J Biomed Sci (2011) 0.79
Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity. Vasc Health Risk Manag (2007) 0.79
Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol (2015) 0.77
Statin-Induced Increases in Atrophy Gene Expression Occur Independently of Changes in PGC1α Protein and Mitochondrial Content. PLoS One (2015) 0.77
Lovastatin exerts protective effects on endothelial cells via upregulation of PTK2B. Exp Ther Med (2016) 0.75
In situ eNOS/NO up-regulation-a simple and effective therapeutic strategy for diabetic skin ulcer. Sci Rep (2016) 0.75
Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol (2017) 0.75
Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers. BMC Surg (2017) 0.75
Biodegradable Polymers Influence the Effect of Atorvastatin on Human Coronary Artery Cells. Int J Mol Sci (2016) 0.75
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Rho GTPases and the actin cytoskeleton. Science (1998) 28.19
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Inflammation and atherosclerosis. Circulation (2002) 20.77
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature (1999) 13.73
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (1999) 11.37
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature (1995) 9.86
Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A (1991) 8.04
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 7.41
Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 5.87
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med (2000) 5.72
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 5.11
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J (1998) 5.09
Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest (1989) 5.01
Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature (1998) 4.65
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Current concepts of the pathogenesis of the acute coronary syndromes. Circulation (2001) 4.23
HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest (2001) 4.11
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet (1996) 3.95
Drug treatment of lipid disorders. N Engl J Med (1999) 3.86
Current perspectives on statins. Circulation (2000) 3.83
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation (1998) 3.63
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med (1995) 3.60
Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation (2002) 3.48
Structural mechanism for statin inhibition of HMG-CoA reductase. Science (2001) 3.45
Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci U S A (1996) 3.29
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation (1997) 3.04
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation (1997) 2.80
Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab (1996) 2.78
Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res (1999) 2.51
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest (1998) 2.39
Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation (2002) 2.39
Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation (2001) 2.38
New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther (1999) 2.29
Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation (2001) 2.14
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem (1997) 2.12
Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem (1995) 2.11
Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res (1989) 1.98
Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol (2002) 1.89
Oxygen reduction by nitric-oxide synthases. J Biol Chem (2001) 1.86
Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation (1995) 1.84
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension (2001) 1.84
Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol (1999) 1.74
The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation (2002) 1.72
Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem (1995) 1.71
Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol (2000) 1.70
Nitric oxide-an endothelial cell survival factor. Cell Death Differ (1999) 1.70
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol (2001) 1.66
Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res (1998) 1.65
Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) Lancet (1995) 1.63
Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation (1999) 1.62
High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem (2000) 1.54
Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest (1992) 1.49
Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation (2001) 1.47
NO: the primary EDRF. J Mol Cell Cardiol (1999) 1.46
Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta (1994) 1.45
Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol (2002) 1.45
Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res (2001) 1.42
Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare? Circulation (2002) 1.42
Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest (1999) 1.42
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation (2000) 1.41
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 1.40
Targeting Rho in cardiovascular disease. Circ Res (2000) 1.38
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res (2002) 1.36
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol (1998) 1.32
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol (1998) 1.29
Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol (2001) 1.16
Nitric oxide regulates monocyte chemotactic protein-1. Circulation (1997) 1.16
Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab (2000) 1.15
A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol (2001) 1.13
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol (2001) 1.11
Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J (2001) 1.07
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res (2001) 1.06
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res (2001) 1.06
Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med (2001) 1.03
Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol (2000) 1.03
Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol (2001) 1.00
Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation (1998) 0.96
Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol (1998) 0.96
Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med (2000) 0.96
Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis (1998) 0.95
Small, dense low-density lipoprotein particles and coronary heart disease risk: A clear association with uncertain implications. JAMA (1996) 0.95
A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis (2001) 0.94
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis (2001) 0.92
Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J Clin Invest (2001) 0.91
Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol (2001) 0.90
Peroxynitrite and atherosclerosis. Biochem Soc Trans (1993) 0.89
Statin-stimulated nitric oxide release from endothelium. Med Sci Monit (2001) 0.87
Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol (1998) 0.86
Relation between endothelial dysfunction and the acute coronary syndrome: implications for therapy. Am J Cardiol (2000) 0.86